Dexmedetomidine Affect Diabetic Patient's Glucose Metabolism (dadpgm)

Shaanxi Provincial People's Hospital

Status and phase: Unknown; Phase 4

Conditions: Diabetes

Treatments: Drug: placebo; Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT02510612

20150618

Details and patient eligibility

About

Dexmedetomidine's Sedative Effect on Diabetic Patient

Full description

Dexmedetomidine is a high selective α2 agonist,its sedative and analgesia feature is acclaimed. The pathogenesis of type 2 diabetes mellitus is associated with α2 excessive adrenaline receptors expression. This study is to evaluate whether the use of dexmedetomidine is helpful to Diabetic Patient through its antisympathetic effect

Enrollment: 120 estimated patients

Sex: All

Ages: 40 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age between 40 and 60
• Selective epigastrium surgery
• In

Exclusion criteria

• American Society of Anesthesiology (ASA) Physical Status>3
• Duration of operation >3 hours
• Hypovolemia,sinus bradycardia,atrioventricular block,severe hepatic and renal dysfunction,severe cardiac insufficiency

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

120 participants in 2 patient groups, including a placebo group

Dexmedetomidine

Experimental group

Description:

Patients in group D will be given dexmedetomidine during anesthesia induction and maintenance phase respectively.In induction phase infuse 1μg/Kg of dexmedetomidine in 10 minutes， the speed in maintenance phase is 0.4μg/Kg.h

Treatment:

Drug: Dexmedetomidine

placebo

Placebo Comparator group

Description:

Patients in group P will be given normal saline during anesthesia induction and maintenance phase

Treatment:

Drug: placebo